European Commission approves Nuceiva to treat glabellar lines. Evolus Inc.

Evolus, Inc. announced that the European Commission (EC) has approved the marketing of Nuceiva (prabotulinumtoxinA). Similar to other neurotoxins marketed in Europe, Nuceiva is approved for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the facial lines has an important psychological impact in adults below 65 years of age.

The EC decision is applicable to all 28 European Union member states plus Iceland, Norway and Liechtenstein. The product was approved by the FDA in February 2019 and launched under the brand name, Jeuveau , in May 2019. Nuceiva� was approved by Health Canada in August 2018. The company expects to launch Nuceiva in Canada in the fourth quarter through its partner Clarion. The company also expects Nuceiva to launch in Europe in 2020.